Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-26
2011-04-26
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C514S001700, C514S013500, C514S021500, C424S805000, C424S810000
Reexamination Certificate
active
07931898
ABSTRACT:
The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.
REFERENCES:
patent: 5180805 (1993-01-01), Gould et al.
patent: 5321123 (1994-06-01), Griffin et al.
patent: 5422258 (1995-06-01), Chang
patent: 5475096 (1995-12-01), Gold et al.
patent: 5514776 (1996-05-01), Chang
patent: 5543144 (1996-08-01), Chang
patent: 5595877 (1997-01-01), Gold et al.
patent: 5629415 (1997-05-01), Hollis et al.
patent: 5653980 (1997-08-01), Hellman
patent: 5660985 (1997-08-01), Pieken et al.
patent: 5670626 (1997-09-01), Chang
patent: 5756291 (1998-05-01), Griffin et al.
patent: 5840867 (1998-11-01), Toole et al.
patent: 5861254 (1999-01-01), Schneider et al.
patent: 5866136 (1999-02-01), Ramshaw et al.
patent: 6025164 (2000-02-01), Bölin et al.
patent: 6110466 (2000-08-01), Lomonossoff et al.
patent: 6180348 (2001-01-01), Li
patent: 6811782 (2004-11-01), Wang et al.
patent: 0419858 (1991-04-01), None
patent: 0955311 (1999-10-01), None
patent: 0957111 (1999-11-01), None
patent: 0383579 (1991-04-01), None
patent: 03123489 (1991-05-01), None
patent: 0440894 (1992-12-01), None
patent: 8906138 (1989-07-01), None
patent: 9531728 (1995-11-01), None
patent: 9733616 (1997-09-01), None
patent: 9931262 (1999-06-01), None
patent: 9949890 (1999-10-01), None
patent: 9954452 (1999-10-01), None
patent: 0053722 (2000-09-01), None
patent: 0058349 (2000-10-01), None
patent: 0058365 (2000-10-01), None
patent: 0102924 (2001-01-01), None
patent: 0157090 (2001-09-01), None
Ishida, et al., “The nucleotide sequence of the mouse immunoglobulin epsilon gene: comparison with the human epsilon gene sequence”,The EMBO Journal, vol. 1, No. 9, pp. 1117-1123, 1982.
Posnett, et al., “A Novel Method for Producing Anti-peptide Antibodies”, The Journal of Biological Chemistry, vol. 263, No. 4, pp. 1719-1825, 1988.
Auriault, et al., “Epitopic Characterization and Vaccinal Potential of Peptides Derived from a Major Antigen of Schistosoma mansoni(Sm28 GST)”,Peptide Research, vol. 4, No. 1, pp. 6-11, 1991.
Patel, et al., “Sequence of the dog immunoglobulin alpha and epsilon constant region genes”, Immunogenetics, 41:282/286, 1995.
Tam, et al., “Multiple Antigen Peptide”, Journal of Immunological Methods, 124, pp. 53-61, 1989.
Hill, et al., “Quantification of serum total IgE concentration in dogs by use of an enzyme-linked immunosorbent assay containing monoclonal murine anti-canine IgE”, Am. J. Vet. Res., vol. 55, No. 7, pp. 944-948, 1994.
Konieczny, et al., “The major dog allergents, Can fl and Can f2, are salivary lipoalin proteins: cloning and immunological characterization of the recombinant forms”, Immunology, 92, pp. 577-586, 1997.
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immunology, 145(1):33-36, 1994.
Tam, “Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system”, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 5409-5413, 1988.
Blind, et al., “Cytoplasmic RNA modulators of an inside-out signal-transduction cascade”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 3606-3610, 1999.
Conry, et al., “Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration”, Clinical Cancer Research, vol. 5, pp. 2330-2337, 1999.
Jameson, et al., “The antigenic index: a novel algorithm for predicting antigenic determinants”, CABIOS, vol. 4, No. 1, pp. 181-186, 1988.
Akhtar, et al., “Cellular uptake and intracellular fate of antisense oligonucleotides”, Trends in Cell Biology, vol. 2, pp. 139-145, 1992.
Maurer, et al., “Lipid-based systems for the intracellular delivery of genetic drugs”, Molecular Membrane Biology, vol. 16, pp. 129-140, 1999.
Hofland, et al.,Formulation and Delivery of Nucleic Acids, Handb. Exp. Pharmacol., Chapter 8, pp. 165-192, 1999.
Conrad, et al.,In Vitro Selection of Nucleic Acid Aptamers that Bind Proteins, Methods of Enzymology, vol. 267, pp. 336-367, 1996.
Köhler, et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, vol. 256, pp. 495-497, 1975.
Neuberger, et al., “A hapten-specific chimaeric IgE antibody with human physiological effector function”, Nature, vol. 314, pp. 268-270, 1985.
Ellington, et al., “In vitro selection of RNA molecules that bind specific ligands”, Nature, vol. 346, pp. 818-822, 1990.
Bock, et al., “Selection of single-stranded DNA molecules that bind and inhibit human thrombin”, Nature, vol. 355, pp. 564-566, 1992.
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science, vol. 247, pp. 1306-1310, 1990.
Cunningham, et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”, Reports, pp. 1081-1085, 1989.
Tuerk, et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase”, Science, pp. 505-510, 1990.
Osborne, et al., “Aptamers as therapeutic and diagnostic reagents: problems and prospects”, Current Opinion in Chemical Biology, pp. 5-9, 1997.
Lee, et al., “Modified Liposome Formulations for Cytosolic Delivery of Macromolecules”, American Chemical Society, pp. 184-192, 2000.
Wilson, et al., “In vitro Selection of Functional Nucleic Acids”, Annu. Rev. Biochem., 68:611-674m 1999.
Aldin, et al., “Antisense oligonucleotides to the GIuR2 AMPA receptor subunit modify excitatory synaptic transmissions in vivo”, Elsevier, 55, pp. 151-164, 1998.
Chun, et al., “Effect of infusion of vasoactive intestinal peptide(VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic suprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats”, Elsevier, 257, pp. 135-138, 1998.
Ghirnikar, et al., “Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides”, Elsevier, 247, pp. 21-24, 1998.
Gold, “Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor”, Neuroscience, vol. 76, No. 4, pp. 1153-1158, 1997.
Dryden, et al., “The lack of specificity of neuropeptide Y(NPY)antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus”, Journal of Endocrinology, 157, pp. 16-175, 1998.
Broaddus, et al., “Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion”, Neurosurg Focus3 (5):1-14, 1997.
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, pp. 433-506, 1994.
Supplemental Partial European Search Report for corresponding European application No. 03814243.6 dated Nov. 7, 2007.
Sutton, et al., “Inhibition of IgE-receptor interactions”, British Medical Bulletin 56 (No. 4):1004-1018, 2000.
Chang, “The pharmacological basis of anti-IgE therapy”, Nature Biotechnology, vol. 18, p. 157-162 (2000).
Babu, et al., “Anti-IgE treatment: an update”, Allergy, 2001:56:1121-1128.
Krah, III Eugene Regis
Lawton Robert
IDEXX Laboratories, Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Szperka Michael
LandOfFree
Methods and compositions for inhibiting binding of IgE to a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting binding of IgE to a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting binding of IgE to a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683652